Drug
Xmt 1522
Xmt 1522: highest development phase Phase 1, developed by Mersana Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Mersana Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| XMT-1522 NCT02952729 | Phase 1 | Advanced Breast Cancer |
Latest
No recent events.
Follow Xmt 1522 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.